Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke

Clinical Pharmacokinetics

Volumn 44, Issue 8, 2005, Pages 863-878

  Jönsson, Siv ^a   Cheng, Yi Fang ^b   Edenius, Charlotte ^c   Lees, Kennedy R ^d   Odergren, Tomas ^b   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c Biolipox AB   (Sweden)

^d WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISUFENTON SODIUM; NITRONE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; COMPARTMENT MODEL; COMPUTER PROGRAM; CREATININE CLEARANCE; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INFUSION; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PARSIMONY ANALYSIS; PRIORITY JOURNAL; STATISTICAL MODEL; STROKE;

ADULT; AGED; AGED, 80 AND OVER; BENZENESULFONATES; CEREBROVASCULAR ACCIDENT; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; NITROGEN OXIDES;

EID: 23744438054     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544080-00007     Document Type: Article

References (25)

1. Kuroda S, Tsuchidate R, Smith ML, et al. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999 Jul; 19: 778-87
2. Zhao Z, Cheng M, Maples KR, et al. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001 Aug 3; 909: 46-50
3. Sydserff SG, Borelli AR, Green AR, et al. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002 Jan; 135: 103-12
4. Marshall JW, Duffin KJ, Green AR, et al. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001 Jan; 32: 190-8
5. Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998 Dec; 18: 667-82
6. Schulz JB, Henshaw DR, Siwek D, et al. Involvement of free radicals in excitotoxicity in vivo. J Neurochem 1995 May; 64: 2239-47
7. Edenius C, Strid S, Borgå O, et al. Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects. J Stroke Cerebrovasc Dis 2002 Jan-Feb; 11: 34-42
8. Lees KR, Sharma AK, Barer D, et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 2001 Mar; 32: 675-80
9. Lees KR, Barer D, Ford GA, et al. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003 Feb; 34: 482-7
10. Strid S, Borga O, Edenius C, et al. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Eur J Clin Pharmacol 2002 Sep; 58: 409-15
11. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000 Dec 12; 55: 1649-55
12. Wahlgren NG, Ranasinha KW, Rosolacci T, et al. Clomethiazole acute stroke study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke 1999 Jan; 30: 21-8
13. Jonsson S, Karlsson MO. A rational approach for selection of optimal covariate-based dosing strategies. Clin Pharmacol Ther 2003 Jan; 73: 7-19
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
15. Markus R, Reutens DC, Kazui S, et al. Topography and temporal evolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke. Stroke 2003 Nov; 34: 2646-52
16. Beal SL, Sheiner LB. NONMEM users guides (I-VIII). Hanover (MD): GloboMax, 1989-1998
17. Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999 Jan; 58: 51-64
18. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. In: D'Argenio DZ, editor. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. New York: Plenum Press, 1995: 69-86
19. Chambers JM, Hastie TJ, editors. Statistical models in S. London: Chapman & Hall, 1993
20. Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res 1998 Sep; 15: 1463-8
21. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 2002; 4: E27
22. Sadray S, Jonsson EN, Karlsson MO. Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection. Pharm Res 1999 Aug; 16: 1260-5
23. Lam YW, Banerji S, Hatfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997 Jan; 32: 30-57
24. Brater DC. Measurement of renal function during drug development. Br J Clin Pharmacol 2002 Jul; 54: 87-95
25. Comstock TJ. Quantification of renal function. In: Dipiro JT, Talbert RL, Hayes PE, editors. Pharmacotherapy: a pathophysiological basis. 3rd ed. Stamford (CT): Appleton-Lange, 1996: 867-85